For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Synthetic peptide: KDLLPPAPPSSGGSRT, corresponding to amino acids 792-806 of the cytoplasmic region of Human FGFR3 with N-terminal added lysine. The peptide is conjugated to KLH with glutaraldehyde.
Fibroblast growth factors (FGFs) are members of a large family of structurally related polypeptides (17-38kD) that are potent physiological regulators of growth and differentiation in a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, in hematopoiesis as well as in tissue remodeling and maintenance. They have also been implicated in pathological conditions such as tumorigenesis and metastasis. The FGF family consists of at least seventeen members designated FGF1 through FGF17. To date, four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg1, cek1], FGFR2 [bek, cek3], FGFR3 [cek2] and FGFR4. Soluble, secreted or possibly cleaved forms of FGFR1 and FGFR2 have also been found in body fluids or were artificially constructed. FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110-150 kD proteins that are constructed of an extracellular ligand binding region with either two or typically three immunoglobulin (Ig)-like domains and an eight amino acid ‘acidic box’, a transmembrane region and a cytoplasmic split tyrosine kinase domain that is activated following ligand binding and receptor dimerization. The ligand binding site of all FGFRs is confined to the extracellular Ig-like domains 2 and 3. FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind several of the FGFs with a similar affinity. Also one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGFs binding to cellular FGFRs depends on, or is markedly facilitated by, the low-affinity interaction of FGFs with the polysaccharide component of cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). For example, perlecan, a basement membrane HSPG, promotes high affinity binding of FGF2 in vitro and angiogenesis in vivo. Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signaling molecules leads to DNA synthesis or differentiation. The signaling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. FGFR3 is widely expressed in many fetal and adult human and animal tissues. FGFR3 expression profile largely correlates with its tissue specific expression at the mRNA level. It is considered the only FGFR expressed in the Organ of Corti of the rat cochlea. Tissue cultured cells transfected with the full length FGFR3 cDNA display the expected membrane localization of the receptor. Interestingly, nuclear localization (nucleoli excluded) of FGFR3 attributable to a 110kD splice variant, has been reported for normal and breast cancer cells. Deletions of chromosome 4p encompassing the FGFR3 gene cause the Wolf-Hirshhorn syndrome (growth failure, mental retardation, cardiac and bone malformations). Achondroplasia is an inherited disorder in which growth abnormality of bone or cartilage leads to skeletal maldevelopment and dwarfism. It is associated with recurrent mutations of a single amino acid in the transmembrane domain of the FGFR3 protein.
The peptide immunogen is conjugated to KLH with glutaraldehyde.
Our Abpromise guarantee covers the use of ab10649 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 110-120 kDa.
1/1000 as determined by western blotting using a whole cell extract of transfected 293T cells expressing recombinant human FGFR3.
1/2000 as determined by immunoprecipitation using a whole cell lysate of transfected 293T cells expressing recombinant human FGFR3.
|IHC-P||1/1 - 1/250.
The epitope(s) recognized by the antibody is resistant to routine formalin-fixation and paraffin embedding.
ICC/IF image of ab10649 stained human HeLa cells. The cells were methanol fixed (5 min) and incubated with the antibody (ab10649, 1µg/ml) for 1h at room temperature. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Image-iTTM FX Signal Enhancer was used as the primary blocking agent, 5% BSA (in TBS-T) was used for all other blocking steps. DAPI was used to stain the cell nuclei (blue). Alexa Fluor® 594 WGA was used to label plasma membranes (red).